MARKET

TTOO

TTOO

T2 Biosystems
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.1985
+0.0036
+1.85%
After Hours: 0.2000 +0.0015 +0.76% 19:08 05/26 EDT
OPEN
0.2000
PREV CLOSE
0.1949
HIGH
0.2089
LOW
0.1950
VOLUME
1.14M
TURNOVER
0
52 WEEK HIGH
1.480
52 WEEK LOW
0.1922
MARKET CAP
34.09M
P/E (TTM)
-0.5927
1D
5D
1M
3M
1Y
5Y
T2 Biosystems stock rises after issuance of U.S. patent for direct detection of Lyme disease
T2 Biosystems (NASDAQ:TTOO) on Friday said the U.S. Patent and Trademark Office had issued a patent for methods and systems to rapidly detect tick-borne pathogens, which also covered the company's
Seekingalpha · 6d ago
T2 Biosystems Announces Issuance Of U.S. Patent For Direct Detection Of Lyme Disease
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Patent and Trademark Office has issued patent number 11,326,213 (the
Benzinga · 6d ago
T2 Biosystems Says It Secured US Patent Covering Method for Direct Detection of Lyme Disease; Shares Rise
MT Newswires · 6d ago
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the commercialization of space technologies and services.
Benzinga · 05/09 10:27
T2 Biosystems stock falls 17% as Q1 net loss widens Y/Y
T2 Biosystems (NASDAQ:TTOO) stock fell May 6, a day after it reported its Q1 results. Q1 revenue rose +4% Y/Y to $7.23M. The company said product revenue declined 17% Y/Y
Seekingalpha · 05/06 15:31
Top Premarket Decliners
MT Newswires · 05/06 08:23
T2 Biosystems Q1 EPS $(0.10) Misses $(0.07) Estimate, Sales $7.20M Beat $6.65M Estimate
T2 Biosystems (NASDAQ:TTOO) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 42.86 percent decrease over losses of $(0.07) per share from
Benzinga · 05/05 21:50
T2 Biosystems Announces Receipt Of Nasdaq Delisting Notice
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that on May 5, 2022 it received a letter from The Nasdaq Stock Market
Benzinga · 05/05 21:07
More
No Data
Learn about the latest financial forecast of TTOO. Analyze the recent business situations of T2 Biosystems through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

66.67%Strong Buy
33.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TTOO stock price target is 0.8833 with a high estimate of 1.000 and a low estimate of 0.6500.
High1.000
Average0.8833
Low0.6500
Current 0.1985
EPS
Actual
Estimate
-0.08-0.06-0.04-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 125
Institutional Holdings: 26.07M
% Owned: 15.18%
Shares Outstanding: 171.73M
TypeInstitutionsShares
Increased
18
1.14M
New
13
264.55K
Decreased
18
4.22M
Sold Out
12
1.02M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.61%
Healthcare Equipment & Supplies
+0.56%
Key Executives
Chairman/President/Chief Executive Officer/Director
John Sperzel
Chief Financial Officer
John Sprague
Chief Operating Officer
Alec Barclay
Vice President/General Counsel
Michael Gibbs
Other
Aparna Ahuja
Other
Brett Giffin
Other
Anthony Pare
Lead Director/Independent Director
John Cumming
Director
Laura Adams
Director
Seymour Liebman
Independent Director
Thierry Bernard
Independent Director
David Elsbree
Independent Director
Ninfa Saunders
Independent Director
Robin Toft
No Data
No Data
About TTOO
T2 Biosystems, Inc. is an in-vitro diagnostics company. The Company is using its T2MR technology, which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its products include the T2Dx Instrument, T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel that are all powered by the T2MR technology. Its development efforts target sepsis. Utilizing T2MR, the Company has developed and received the United States Federal Drug Administration marketing clearance for the T2Dx Instrument, an instrument for detecting pathogens associated with sepsis and Lyme disease, as well as other applications. Its T2SARS-CoV-2 Panel is designed to detect SARS-CoV-2, the virus that is responsible for COVID-19 infections.

Webull offers kinds of T2 Biosystems Inc stock information, including NASDAQ:TTOO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTOO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TTOO stock methods without spending real money on the virtual paper trading platform.